INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7401, 272, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7402, 322, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7403, 4254, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7404, 8095, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7405, 21220, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7406, 142, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7407, 272, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7408, 322, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7409, 4254, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7410, 8095, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7411, 21220, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7412, 142, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7413, 272, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7414, 322, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7415, 4254, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7416, 8095, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7417, 21220, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7418, 142, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7419, 272, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7420, 322, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7421, 4254, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7422, 8095, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7423, 21220, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7424, 7196, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7425, 11072, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7426, 11073, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7427, 14146, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7428, 20022, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7429, 28077, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7430, 7196, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7431, 11072, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7432, 11073, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7433, 14146, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7434, 20022, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7435, 28077, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7436, 7196, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7437, 11072, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7438, 11073, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7439, 14146, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7440, 20022, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7441, 28077, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7442, 7196, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7443, 11072, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7444, 11073, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7445, 14146, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7446, 20022, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7447, 28077, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7448, 7196, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7449, 11072, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7450, 11073, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7451, 14146, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7452, 20022, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7453, 28077, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7454, 7196, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7455, 11072, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7456, 11073, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7457, 14146, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7458, 20022, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7459, 28077, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7460, 7196, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7461, 11072, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7462, 11073, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7463, 14146, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7464, 20022, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7465, 28077, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7466, 7196, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7467, 11072, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7468, 11073, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7469, 14146, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7470, 20022, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7471, 28077, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7472, 7196, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7473, 11072, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7474, 11073, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7475, 14146, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7476, 20022, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7477, 28077, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7478, 7196, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7479, 11072, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7480, 11073, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7481, 14146, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7482, 20022, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7483, 28077, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7484, 516, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7485, 2797, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7486, 7824, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7487, 7825, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7488, 7826, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7489, 7827, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7490, 7828, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7491, 8097, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7492, 25000, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7493, 25001, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7494, 25002, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7495, 25257, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7496, 25259, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7497, 25261, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7498, 27683, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7499, 29582, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7500, 29583, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', '', 'DDInter', 0);
